Journey Medical Corp
DERM evidence brief
What we can confirm
- BioSniper Score:
- 8.7 / 10
- Market Cap:
- $204.1M
- Lead Asset:
- Accutane (Approved)
What it means
What to watch
Prepared research question
What matters most for DERM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DERM
Journey Medical Corp (DERM) is a commercial-stage pharmaceutical company focused on selling and marketing FDA-approved prescription products for dermatological conditions, with a current portfolio of nine approved drugs and a recently launched rosacea treatment, Emrosi.
Key risk: Net loss position
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 6 pipeline candidates · 3 clinical trials · 4 catalysts · 5 FDA decisions for Journey Medical Corp.
Journey Medical Corp (DERM) is a commercial-stage pharmaceutical company focused on selling and marketing FDA-approved prescription products for dermatological conditions, with a current portfolio of nine approved drugs and a recently launched rosacea treatment, Emrosi.
- Commercial-stage pharmaceutical company founded in October 2014, focusing on dermatological prescription products [sec_mda · as of 2026-08-12].
- Current portfolio includes nine FDA-approved prescription pharmaceutical products [sec_mda · as of 2026-08-12].
- Emrosi (minocycline hydrochloride) was approved by the FDA on November 1, 2024, for inflammatory lesions of rosacea in adults [sec_mda · as of 2026-03-26].
- Cash & equivalents of $25.6M as of 2026-06-30 [sec]; net income of -$0.3M for the same period [sec].
- Total revenues for Q1 2026 were $16.0M, a 21% year-over-year increase [news · published 2026-05-13].
What works
- Emrosi generated $14.7M in net revenues in FY2025 after its April 2025 launch, with approximately 53,000 prescriptions filled [news · published 2026-03-25].
- Payer access for Emrosi is available to over 100 million U.S. commercial lives [news · published 2026-03-25].
- Cash position increased to $27M in Q1 2026, driven by strong financial performance [news · published 2026-05-13].
- Company is managed by experienced life science executives with a track record of bringing novel medicines to market [sec_mda · as of 2026-03-26].
What to weigh
- Net income was -$0.3M as of 2026-06-30, indicating ongoing net losses [sec].
- Total debt of $26.2M as of 2026-06-30 is nearly equal to cash & equivalents of $25.6M [sec].
- The company relies on cash from product sales and external financing (term loan credit facility and at-the-market sales program) to meet capital needs [sec_mda · as of 2026-03-26].
- A $1.3M non-cash charge related to inventory acquired in the 2021 Qbrexza asset acquisition impacted financial results [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
Company focus and founding date
“We are a commercial-stage pharmaceutical company founded in October 2014 that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions.”
SEC MD&A · August 12, 2026
Emrosi FDA approval date and indication
“On November 1, 2024, the FDA approved Emrosi, for the treatment of inflammatory lesions of rosacea in adults.”
SEC MD&A · March 26, 2026
Q1 2026 revenue and cash position
“Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased to $27 million, driven by strong financial performance”
News · May 13, 2026
FY2025 Emrosi net revenues and prescriptions
“Emrosi™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately 53,000 total prescriptions were filled for Emrosi™ during FY2025”
News · March 25, 2026
Catalyst timeline
- 2030-10-01 · Patent_Expiry · MINOCYCLINE HYDROCHLORIDE — Patent_Expiry: NDA213690 — Patent expiry for a minocycline hydrochloride product; may affect exclusivity and competition.
- 2033-02-28 · Patent_Expiry · GLYCOPYRRONIUM TOSYLATE — Patent_Expiry: NDA210361 — Patent expiry for glycopyrronium tosylate; potential generic entry.
- 2037-09-08 · Patent_Expiry · MINOCYCLINE HYDROCHLORIDE — Patent_Expiry: NDA212379 — Patent expiry for another minocycline hydrochloride product.
- 2039-01-07 · Patent_Expiry · MINOCYCLINE HYDROCHLORIDE — Patent_Expiry: NDA219015 — Patent expiry for a third minocycline hydrochloride product.
Risks & what to watch (4)›
Key risks
- Net loss position — Net income of -$0.3M as of 2026-06-30 indicates the company is not yet profitable [sec].
- High debt relative to cash — Total debt of $26.2M nearly equals cash & equivalents of $25.6M as of 2026-06-30, limiting financial flexibility [sec].
- Dependence on Emrosi success — Emrosi is a key growth driver; any setback in payer coverage or prescription growth could materially impact revenue [news · published 2026-03-25].
- Reliance on external financing — Company uses term loan credit facility and at-the-market sales program to meet capital needs, indicating potential cash flow constraints [sec_mda · as of 2026-03-26].
What to watch
- Emrosi prescription growth and payer coverage expansion, as it is the primary growth driver [news · published 2026-03-25].
- Ability to achieve sustained profitability given current net loss position [sec].
- Management of debt levels relative to cash reserves [sec].
- Progress of the proof-of-concept study for roflumilast foam 0.3% in pediatric vitiligo, initiated in August 2025 [catalyst].
Sources: Catalysts · News · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Journey Medical Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Journey Medical Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 2.06 · 0% dilution
Lead: Approved
6 candidates
4 upcoming, next in ~1448d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 24.5%
- Days to cover
- 17.6
- Shares short
- 3,674,135
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DERM short interestGovernance
Frequently asked questions
What is the AI investment thesis for Journey Medical Corp?
Journey Medical Corp (DERM) is a commercial-stage pharmaceutical company focused on selling and marketing FDA-approved prescription products for dermatological conditions, with a current portfolio of nine approved drugs and a recently launched rosacea treatment, Emrosi.
What is Journey Medical Corp's lead drug candidate?
Journey Medical Corp's most advanced tracked candidate is Accutane (Approved) for Severe recalcitrant nodular acne.
What is Journey Medical Corp's next catalyst?
Journey Medical Corp's next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA213690" — expected October 1, 2030.
Who is the CEO of Journey Medical Corp?
Mr. Claude Maraoui is the chief executive officer of Journey Medical Corp (DERM).
Where is Journey Medical Corp headquartered?
Journey Medical Corp (DERM) is headquartered in Scottsdale, AZ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.